Nintedanib 13CD3
| Product Name | Nintedanib 13CD3 |
|---|---|
| Alternate Names | Nintedanib Stable Isotopes, Stable Isotopes of Nintedanib |
| CAT No. | CS-O-14348 |
| CAS No. | 656247-17-5 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 543.64 g/mol |
| Mol. For. | C₃₀¹³CH₃₀D₃N₅O₄ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Nintedanib |
| Purity | Not less than 90 % |
| Smileys | O=C1/C(C2=CC=C(C(OC)=O)C=C2N1)=C(C3=CC=CC=C3)\NC4=CC=C(N(C)C(CN5CCN([13C]([2H])([2H])[2H])CC5)=O)C=C4 |
| Canonical Smiles | CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O |
| InchIKey | CPMDPSXJELVGJG-UHFFFAOYSA-N |
| Inchl | InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3 |
| IUPAC | methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Nintedanib 13CD3 is a drug used to treat idiopathic pulmonary fibrosis (IPF), a condition where the lungs become scarred and stiff, making it difficult to breathe. It is a tyrosine kinase inhibitor that works by blocking certain enzymes that stimulate the growth of cells involved in the scarring of lung tissue. By doing so, it slows down the progression of IPF and reduces the risk of acute exacerbations.
The chemical structure of Nintedanib 13CD3 is similar to that of the non-labeled Nintedanib, but it contains three deuterium atoms, which are stable isotopes of hydrogen. This labeling technique is used to improve the drug’s pharmacokinetics and reduce variability in drug metabolism, leading to more consistent efficacy and safety profiles.
Nintedanib 13CD3 is available as a capsule for oral administration and is usually taken twice a day with food. Common side effects include diarrhea, nausea, vomiting, abdominal pain, and decreased appetite. It may also cause liver toxicity and bleeding, so regular monitoring of liver function tests and blood clotting parameters is recommended.
Overall, Nintedanib 13CD3 is an important treatment option for patients with IPF, and its labeled structure provides improved pharmacokinetic properties that enhance its therapeutic benefits.
Get an Instant Quote
Related Compounds
Nintedanib D8 |